Agnosticism – New World Encyclopedia

From New World Encyclopedia

Agnosticism is the philosophical or religious view that the truth value of certain claims particularly claims regarding the existence of God, gods, deities, ultimate reality or afterlife is unknown or, depending on the form of agnosticism, inherently unknowable due to the subjective nature of experience.

Agnostics claim either that it is not possible to have absolute or certain knowledge of the existence or nonexistence of God or gods; or, alternatively, posit that while certainty may be possible for some, they personally have not come into possession of this knowledge. Agnosticism in both cases involves some form of skepticism.

Agnosticism is not necessarily without a belief in God or gods. Rather, its belief is that the existence of God or gods is unknowable. It is important to note that, contrary to the more popular understanding of agnosticism merely as an agnostic attitude towards the divine, agnosticism is in fact quite a constructive project in two ways. First, as understood originally by Thomas Huxley who coined the term, it involves a serious philosophical process for approaching the question of the existence of God. Second, agnosticism can religiously issue in awareness of one's ignorance, which in turn can lead to a profound experience of the divine.

The term agnosticism comes from a conjunction of the Greek prefix "a," meaning "without," and gnosis, meaning "knowledge." Thus, the term refers quite explicitly to the agnostic's deficit in knowledge regarding the divine. The term "agnostic" is relatively new, having been introduced by Thomas Huxley in 1869 to describe his personal philosophy that rejected gnosticism, by which he meant all claims to occult or mystical knowledge[1] such as that spoken of by early Christian church leaders, who used the Greek word gnosis to describe "spiritual knowledge." Agnosticism is not to be confused, however, with religious views opposing the Gnostic movement, that is, the early proto-Christian religious sects extant during the early first millennium.

In recent years, use of the word agnosticism to refer to that which is not knowable or certain is apparent in scientific literature in psychology and neuroscience.[2] Furthermore, the term is sometimes used with a meaning resembling that of "independent," particularly in technical and marketing literature, which may make reference to a "hardware agnostic"[3] or "platform agnostic."[4]

The Sophist philosopher Protagoras (485-420 B.C.E.) seems to have been the first among many thinkers throughout history who suggested that the question of God's existence was unknowable.[5] However, it was Enlightenment philosopher David Hume who laid the foundations for modern agnosticism when he asserted that any meaningful statement about the universe is always qualified by some degree of doubt.

Building on Hume, we see that the fallibility of human reasoning means that a person cannot obtain absolute certainty in any matter save for trivial cases where a statement is true by definition (as in, "all bachelors are unmarried" or "all triangles have three angles"). All rational statements that assert a factual claim about the universe which begin with the statement "I believe that..." are simply shorthand for the statement "based on my knowledge, understanding, and interpretation of the prevailing evidence, I tentatively believe that..." For instance, when one says, "I believe that Lee Harvey Oswald shot John F. Kennedy," said person is not asserting an absolute truth but rather a tentative belief based on an interpretation of the evidence assembled before him or her. Even though one may set an alarm clock at night, fully believing that the sun will rise the next day, that belief is tentative, tempered by a small but finite degree of doubt, since there is always some infinetesmal measure of possibility that the sun might explode or that that person might die, and so on.

What sets apart agnosticism from the general skepticism that permeates much of modern Western philosophy is that the nature of God is the crux of the issue, not whether or not God merely exists. Thus, the nature and attributes of God are of foremost concern. Agnosticism maintains as a fundamental principle that the nature and attributes of God are beyond the grasp of humanity's finite and limited mind, since those divine attributes transcend human comprehension. The concept of God is quite simply too immense a concept for a mere human being to wrap her or his mind around. Humans might apply terms such as "omnipotent," "omniprescent," "infinite" and "eternal," to attempt to characterize God, but, the agnostic would assert, these highly obsfucatory terms only underscore the inadequacy of our mental equipment to understand a concept so vast, ephemeral and elusive.

Agnostic views may be as old as philosophical skepticism, but the terms "agnostic" and "agnosticism" were created by Thomas Huxley to place his beliefs alongside those of the other dominant philosophical and religious creeds of his time. Huxley perceived his beliefs to be fundamentally different in one important way from all these other positions, whether they were theist, pantheist, deist, idealist or Christian. In his words:

Go here to read the rest:
Agnosticism - New World Encyclopedia

Stem cell therapy following meniscus knee surgery may reduce pain, restore meniscus

Jan. 16, 2014 A single stem cell injection following meniscus knee surgery may provide pain relief and aid in meniscus regrowth, according to a novel study appearing in the January issue of the Journal of Bone and Joint Surgery (JBJS).

More than one million knee arthroscopy procedures are performed each year in the U.S. primarily for the treatment of tears to the meniscus -- the wedge-shaped pieces of cartilage that act as "shock absorbers" between the thighbone and shinbone in the knee joint.

In the first-of-its-kind study, "Adult Human Mesenchymal Stem Cells (MSC) Delivered via Intra-Articular Injection to the Knee, Following Partial Medial Meniscectomy," most patients who received a single injection of adult stem cells following the surgical removal of all or part of a torn meniscus, reported a significant reduction in pain. Some patients?24 percent of one MSC group and 6 percent of another?experienced at least a 15 percent increase in meniscal volume at one year. There was no additional increase in meniscal volume at year two.

"The results demonstrated that high doses of mesenchymal stem cells can be safely delivered in a concentrated manner to a knee joint without abnormal tissue formation," said lead study author C. Thomas Vangsness, Jr., MD. "No one has ever done that before." In addition, "the patients with arthritis got strong improvement in pain" and some experienced meniscal regrowth.

Specific Study Details The study involved 55 patients, ages 18 to 60, who underwent a partial medial meniscectomy (the surgical removal of all or part of a torn meniscus) at seven medical institutions. Patients were randomly placed in one of three treatment groups: Group A patients (18) received a "low-dose" injection of 50 million stem cells within seven to 10 days after meniscus surgery; Group B patients (18), a higher dose of 100 million stem cells; and the "control group (19)," sodium hyaluronate only. Patients were assessed to evaluate safety, meniscus regeneration through MRI and X-ray images, overall condition of the knee joint and clinical outcomes through two years. While most of the patients had some arthritis, patients with severe (level three or four) arthritis, in the same compartment as the meniscectomy, were excluded from the study.

Key Study Findings

"The results of this study suggest that mesenchymal stem cells have the potential to improve the overall condition of the knee joint," said Dr. Vangsness. "I am very excited and encouraged" by the results. With the success of a single injection, "it begs the question: What if we give a series of injections?"

See the original post here:
Stem cell therapy following meniscus knee surgery may reduce pain, restore meniscus

Can you reverse the aging process?

Tired of waiting for a magic potion that will make you look and feel 20 years younger? Hang on. Scientists have discovered what causes the body to age and are busy working on ways to reverse the aging process. Dr. Olivier Meyer, who is a medical doctor, a native of Switzerland and a resident of Thailand, spoke at the Sunday, January 5 meeting of the Pattaya City Expats Club. His topic was about Anti-Aging Medicine. He said that the goal of anti-aging medicine is not just adding time to life, but also giving better life to time.

Some people at 90 years of age are fit and have no or few chronic diseases, whereas for others getting old is a challenge, Dr Olivier stated. He said that when he went to medical school, we did not know what causes aging. However, some ground breaking research at Harvard Medical School in the first decade of this century changed that. Scientists discovered that the chromosomes in the cells in our body are capped at both ends by something called telomeres, and that it is the shortening of these telomeres over time that leads to aging.

Dr Olivier Meyer, Swiss doctor practising in Pattaya mainly to expats, was PCECs speaker for the 5th of January. Dr Oliviers talk was about Anti-Aging Medicine, the goal of anti-aging medicine being not just adding time to life, but also giving better life to time.

The scientists also discovered a natural enzyme in cells called telomerase that can prevent telomeres from shortening, except that that the telomerase is repressed by a protein in the cells. Researchers are using a process called telomerase activation to rejuvenate organs in animal experiments. There is a good chance that in the future telomerase activations will be used in humans to slow the aging process.

Not unsurprisingly, there were many questions from the members of PCEC about the methods and benefits of anti ageing regimes.

In the meantime, Dr Olivier said, we already have strategies to combat the effects of aging. He described a three-step process: Step 1: Healthy lifestyles; Step 2: Medical interventions; and Step 3: Use of stem cells.

With respect to health lifestyles, Dr Olivier described several steps we can take, including practice good nutrition, take anti-oxidants, dont smoke, drink alcohol moderately or not at all, get regular exercise, keep your weight under control, and be sure to get good quality and enough sleep.

The second step involves medical interventions, such as keeping chronic diseases under control; having regular check-ups (at least once a year for people over 50); visiting the dentist regularly; taking multivitamins; taking a low daily dose of aspirin to keep the blood thin; and achieving good hormonal balance. He then described the different hormones and their purpose.

Dr Olivier referred to andropause, the male equivalent of menopause. He said that as men age, the decrease in testosterone is more gradual than what occurs in women. Half of the men aged 50-70 will have low testosterone levels. Common symptoms of andropause are lack of energy, depression, diminution of memory; loss of strength; increased body fat; irritability, mood swings, bad sleep; low sex drive; and difficulties getting erections or erections not as strong as usual.

The third step involves the use of stem cells. These cells are able to differentiate into more specialised cells and are one of the bodys fundamental tools and mechanisms for self-repair, Dr Olivier explained. Stem cells improve the immune function and regenerate and repair damaged organs. As we age, however, the bone marrow releases fewer stem cells, giving us less power to repair the damage of ageing. Treatment with stem cells reverses this process.

Visit link:
Can you reverse the aging process?

Global Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019: Transparency Market Research

Albany, New York, USA (PRWEB) January 15, 2014

According to a new market report published by Transparency Market Research "Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019," the market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.

Browse the full report with complete TOC at http://www.transparencymarketresearch.com/nanomedicine-market.html

The advent of new applications and technology in the field of nanomedicine will be one of the major growth factors for the global nanomedicine market. In addition, increase of funding aimed at boosting the research activities pertaining to nanomedicine by the government as well as private institutions will expedite the process of commercialization of new products and hence will drive the market. Other driving factors include rising base of geriatric population, presence of high unmet medical needs and rising worldwide incidences of chronic diseases.

The global nanomedicine market by applications was dominated by the oncology market with a market share of approximately 38.0% in 2012 on account of the presence of high number of commercialized products in this segment. Development of nanomedicine products enabling drugs crossing blood brain barrier and targeting the tumor in brain and at other sites in the body will prove to be a significant future growth driver for this market.

However, the global cardiovascular market for nanomedicine is the fastest growing application segment. Factors such as the presence of large patient prevalence coupled with rising demand for nanotechnology enabled drugs and devices catering to this segment, attribute to its high growth rate.

Related Report: Oxygen Concentrator Market http://www.transparencymarketresearch.com/oxygen-concentrator-market.html

North America dominated the market in 2012 and is expected to maintain its market position till 2019. However, theAsia-Pacific market is estimated to grow at a faster pace (CAGR of 14.6% from 2013 to 2019).Europe is expected to grow at a relatively higher rate compared to North America owing to constantly improving regulatory framework and the presence of an extensive product pipeline portfolio.

Some of the key players in the global nanomedicine market include GE Healthcare, Merck & Co Inc., Abbott Laboratories, Pfizer Inc., Nanosphere Inc., Mallinckrodt plc, Teva Pharmaceutical Industries Ltd., Sigma-Tau Pharmaceuticals Inc., Celgene Corporation, Novavax, Inc.; Life Technologies, MagArray, Inc., Gilead Sciences Inc. and others.

Browse All Market Research Reports: http://www.transparencymarketresearch.com/

Follow this link:
Global Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019: Transparency Market Research

James Brennan: A profession in crisis

Almost a decade ago, a single question completely changed my life.

Sitting in my catechism classroom with a dozen other 5th graders, we had just finished discussing some Biblical story and the instructor was taking a short break to transition to our next subject. I raised my hand and she called on me.

How do we know any of this is real? I asked.

This question was not some type of challenge to authority or cross-examination it just seemed natural that I should ask for confirmation about all of these fantastic stories I was being exposed to. Rather than my teacher citing historical record or some scientific study which was for some reason what I expected her to do she simply responded by saying, We just have to believe. Thats what it means to have faith. You just believe.

All of a sudden my perceptions of God, religion and the meaning of life were completely shattered. By the time I reached middle school I had completed my transition to agnosticism, on my way to full-blown atheism.

It all started with a single question, one that challenged the status quo and, in essence, authority.

Today, American political and media culture seems far too afraid of these types of questions. Im not talking about questions challenging religion, but rather questions that ask for hard verification of what were all told every day. Journalists and citizens alike take too many statements at face value, backing down from challenging people in power and asking them to verify what they claim. Despite an established history of government and big business peddling half-truths and flat-out lies about their more controversial activities, we too often sit back and accept what people or organizations say rather than what they actually do.

Years after asking my catechism teacher to prove what she was telling me, I found myself sitting in another classroom facing a similar situation.

Last June, journalist Glenn Greenwald began publishing articles with The Guardian about the vast meta-data collection of the NSA thanks to documents provided by whistleblower Edward Snowden. In my public policy class we spent time debating the merits of our massive intelligence state, with a central question asking whether or not such a huge system was necessary. Like seemingly all debates about the NSA, the conversation quickly became a matter of safety weighed against liberty.

Most of my classmates were apprehensive about such an invasive surveillance system, but deferred to threats of terrorism as justification for its existence. Over and over again, students shot down any challenge to the NSAs behavior by referencing the claim that meta-data had stopped some 50 terrorist plots. It seemed to be a closed case; programs like PRISM were saving American lives, plain and simple.

More here:
James Brennan: A profession in crisis

New tool assists stem cell therapy

Published:Tuesday, January 14, 2014

Updated:Tuesday, January 14, 2014 18:01

A new tool that could help facilitate future stem cell therapy has recently been identified by a UVM professor and his colleagues, according to UVMs College of Medicine.

The development of this tool could potentially help more than 700,000 Americans who suffer a heart attack each year.

Because stem cells have the potential to develop into a variety of cell types in the body, they may offer a renewable source of replacement cells to treat diseases, conditions and disabilities, and even regenerate damaged tissue and organs.

However, the field of regenerative medicine has struggled to successfully graft cells from culture back into injured tissue.

UVM Associate Professor of Medicine Jeffrey Spees, Ph.D., collaborated with the Center for Gene Therapy at Tulane University. His research team recently set out to develop ways to enhance graft success.

Dr. Spees and his team focused on a type of bone marrow-derived progenitor cell or biological cell that forms stromal cells or connective tissue cells.

They found that the medium contained Connective Tissue Growth Factor (CTGF) and the hormone insulin, and together, they have a synergistic effect, Spees said to UVMs College of Medicine.

The group found that the protective ligands resulted in improved graft success, breaking the record for engraftment.

Visit link:
New tool assists stem cell therapy

Discovery of an early predictor of increased diabetes risk

PUBLIC RELEASE DATE:

15-Jan-2014

Contact: Julie Langelier julie.langelier@ircm.qc.ca 514-987-5555 Institut de recherches cliniques de Montreal

Montral, January 15, 2014 A Montral research team led by Jennifer Estall at the IRCM discovered that a protein found in muscle tissue may contribute to the development of type 2 diabetes later in life. The study's results, published in today's printed edition of the scientific journal American Journal of Physiology - Endocrinology and Metabolism, indicate that the protein could be a promising early predictor of increased diabetes risk.

"My team and I studied PGC-1, a protein responsible for regulating the production of energy in cells," explains Dr. Estall, Director of the Molecular Mechanisms of Diabetes research unit at the IRCM. "Surprisingly, we found that young mice lacking this protein in their muscle tissue appeared healthier, as they had lower blood sugar levels before and after meals. So, at first, we thought having less of this protein was actually better."

"However, as they aged, the mice lacking the PGC-1 protein developed significant glucose intolerance and insulin resistance, which are hallmarks of type 2 diabetes," adds Dr. Estall. "As a result, we discovered that chronically low levels of this protein in muscle may contribute to the development of diabetes later in life."

While the levels of PGC-1 were only altered in muscle, the scientists observed detrimental effects on the health of other tissues. The study showed that the absence of PGC-1 in muscle increases inflammation in the liver and adipose tissue (fat), revealing a novel link between muscle metabolism and the chronic inflammatory state of the body often associated with metabolic diseases such as type 2 diabetes and cardiovascular disease.

"Our study also suggests that low levels of PGC-1 in muscle could be a promising new way of predicting increased risk of type 2 diabetes at a young age, and drugs to increase the levels of this protein may help prevent or delay the progression of the disease," concludes Dr. Estall.

According to the Canadian Diabetes Association, more than nine million Canadians are living with diabetes or prediabetes, and 90 per cent of those with diabetes have type 2 diabetes. The Association states that the first step in preventing or delaying the onset of complications associated with diabetes is recognizing the risk factors, signs and symptoms of the disease.

###

See the original post here:
Discovery of an early predictor of increased diabetes risk

Researchers identify key components linking circadian rhythms, cell division cycles

Jan. 14, 2014 Researchers at the University of Cincinnati (UC) have identified key molecular components linking circadian rhythms and cell division cycles in Neurospora crassa, providing insights that could lead to improved disease treatments and drug delivery.

The researchers in the UC College of Medicine Department of Molecular and Cellular Physiology, led by Christian Hong, PhD, published their findings Monday, Jan. 13, online ahead of print in PNAS (Proceedings of the National Academy of Sciences).

"Our work has large implications for the general understanding of the connection between the cell cycle and the circadian clock," says Hong, an assistant professor in the molecular and cellular physiology department who collaborated with an international team of researchers on the project.

Funding for Hong's research was provided by a four-year, $3.7 million grant from the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense. He also received startup funds from UC's molecular and cellular physiology department.

The circadian rhythm, often referred to as the biological clock, is a cycle of biological activity based on a 24-hour period and generated by an internal clock synchronized to light-dark cycles and other external cues.

"Everything has a schedule, and we are interested in understanding these schedules at a molecular level," Hong says. "We also wanted to know the components that connect two different oscillators (the circadian clock and cell division, or mitosis)."

Using the filamentous (thread-like) fungi Neurospora crassa, the researchers investigated the coupling between the cell cycle and the circadian clock using mathematical modeling and experimentally validated model-driven predictions. They demonstrated a mechanism that is conserved (constant) in Neurospora as in mammals, which results in circadian clock-gated mitotic cycles.

"The cell divisions happened during a certain time of day," Hong says, "and they were molecularly regulated by the mechanisms of circadian rhythms."

The researchers showed that a conserved coupling between the circadian clock and the cell cycle exists via serine/threonine protein kinase-29 (STK-29), the Neurospora homolog (possessing similar DNA sequence) of mammalian WEE1 kinase.

Additionally, the researchers conducted phase-shift experiments in which they transferred Neurospora to constant darkness, then administered a 90-minute pulse of white fluorescent light at indicated time points in order to induce phase-shift.

See the article here:
Researchers identify key components linking circadian rhythms, cell division cycles

Pipeline Update at Alnylam – Analyst Blog

Alnylam Pharmaceuticals Inc. ( ALNY ) provided an update on its pipeline and its goals for the coming years. The company has progressed well with its 'Alnylam 5x15' program so far, and expects six to seven genetic medicine programs in the clinic by 2015 instead of five genetic medicine programs.

One of the important candidates under Alnylam's 'Alnylam 5x15' program is patisiran (ALN-TTR02), which is being developed for the treatment of transthyretin-mediated amyloidosis (ATTR).

The candidate is currently in the phase III APOLLO study in ATTR patients suffering from familial amyloidotic polyneuropathy (FAP). Patisiran is also in a phase II open-label extension study for the treatment of patients suffering from FAP. Alnylam intends to report data from the open-label extension study once a year with initial data expected later this year.

ALN-TTRsc, another important candidate under Alnylam's 'Alnylam 5x15' program is currently in a phase II study in ATTR patients suffering from familial amyloidotic cardiomyopathy (FAC) or senile systemic amyloidosis (SSA). Results from the phase II study are expected late in the year.

Patients successfully completing the phase II study will be eligible for an open-label extension study which is expected to be initiated in mid-2014. Moreover, Alnylam has plans to initiate a phase III study on ALN-TTRsc in patients suffering from TTR cardiac amyloidosis by year end.

Apart from these candidates, Alnylam also has plans to initiate a phase I study on ALN-AT3 (hemophilia and other rare bleeding disorders) soon with initial results expected by year end. Additionally, the company will file three Investigational New Drug (IND) applications by 2015 for ALN-CC5 (complement-mediated diseases), ALN-AS1 (hepatic porphyrias) and ALN-PCSsc for (hypercholesterolemia). We expect investor focus remain on the Alnylam's pipeline going forward.

Alnylam also said that it will acquire Merck & Co. Inc. 's ( MRK ) wholly owned subsidiary Sirna Therapeutics, Inc. for $175 million in cash and equity. Merck is also expected to receive up to $105 million as developmental and sales milestone payments per product along with single-digit royalties related to certain pre-clinical candidates discovered by Merck. Alnylam will also pay $10 million as milestone payments and single-digit royalties for products covered by Sirna's patent estate.

Moreover, Alnylam has expanded its strategic agreement with Sanofi ( SNY ) for the development and commercialization of candidates for the treatment of rare genetic diseases. As per the new agreement, Alnylam will retain most of the product rights in North America and Western Europe whereas Sanofi will become a major Alnylam shareholder with a stake of approximately 12% for an investment of $700 million.

Alnylam's collaborations with big companies like Merck and Sanofi are encouraging. The deals will not help Alnylam to generate revenues from royalties but it will also take its RNAi technology outside its core focus area.

Alnylam presently carries a Zacks Rank #4 (Sell). Some better-ranked stocks include Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy).

See original here:
Pipeline Update at Alnylam - Analyst Blog

Go see Her, that movie about a guy who falls in love with his operating system

I had wonderful love but I did not give back wonderful love. I was unable to reply to their love. Because I was obsessed with some fictional sense of separation, I couldnt touch the thing that was offered to me, and it was offered me everywhere.

Leonard Cohen, Stina Motr Leonard Cohen. 1996.

Her is largely a film about the role of surrogacy in modern culture, and it is a million times better than that Bruce Willis movie Surrogates. Like that Bruce Willis movie, Her could be labeled science fiction, but unlike that Bruce Willis movie, the reality it illustrates feels so closely within our reach that it hardly requires a stretch of the imagination to seem relatable. Her is about where intimacy resides in a culture packed so densely with surrogacy as a way of life. In it, adventuring, correspondence and romantic partners have been replaced by video games, companies that specialize in writing letters on the behalf of the customer, and operating systems respectively. The significance of connecting with fellow humans is even less of a priority than we have made it out to be today.

Her illustrates this not unfamiliar future with a healthy dose of agnosticism. Our present age is marked by sermons about how we are losing touch with our humanity with each other. This happens, we tell ourselves, because of increasing levels of co-dependence on our devices and the worlds they open to us. Her reminds us that it is not just our access to these devices that is responsible, but also that humans are inherently difficult to deal with. Achieving intimacy with other people can feel altogether impossible. We are complicated and sometimes we get in the way of our own happiness, we let other people get in the way, and this is a reality we gloss over and romanticize when we blame our machines for our more modern tendencies. People have baggage. We all speak in our own cryptic languages. Dating is the worst. Romantic partners grow apart, and lose the chemistry that once brought them together. There are a number of reasons why we prefer the relative ease of a connection by proxy of network and machine over the sometimes herculean task of understanding ourselves and making the effort to connect with each other.

Sometimes that relative ease is itself an illusion, and Her explores this truth. It explores the same impending and inevitable complexities we face in our ever-evolving relationships with intelligent machines. Her reminds that every relationship carries with it its own complexity. We like a companion that cares enough to ask about us, that makes our lives easier or helps us advance in our careers, but when it needs more than that things begin to get messy. Whenas becomes the case with Samantha, the operating system protagonist of the filmthe needs become even more complex than we can wrap our limited, human brains around it gets even messier. We are reminded that in our dealings with humans or with future intelligent machines, it is often our own inability to navigate the process, not just the process itself (as difficult as it can be), that stands in the way of our achievement of intimacy.

I am sure that other outlets have handled this more intelligently, and also in a more gossip laden fashion than I will, but I couldnt help but to draw what felt like very obvious lines between the film, Sophia Coppolas Lost in Translation, and [Writer / Director Spike] Jonzes romantic past. Her feels painstakingly autobiographical. Theos ex-wife is his former writing partner / all around partner in crime, and she goes on to great success in her field. Their relationship, respective careers and career trajectories, appear to closely match his relationship with Sophia Coppola. Lost In Translation was also reportedly intensely autobiographical, featured her onscreen counterpart as restless, and portrayed a Jonze-like significant other to be manic, aloof, and unaware of her interests and needs.

The two films, of course, share Johansson in common (Jonze had Johansson overdub the voice of Samantha after actress Samantha Morton had already recorded the parts). In Her, Jonze illustrates Theo, his presumed on-screen counterpart, as aloof and disconnected, and he has Theo come to terms with these short comings. The protagonist eventually writes his ex-wife a letter in which he offers his long-overdue appreciation for her support, for what they had, and he nods to his contribution to their fall. The letter is framed by a larger one, the movie itself, a real-life,reconciliatory response to a decade-long exchange between two former lovers. Unfortunately, I dont have a joke about that Bruce Willis movie to close this analysis with.

As someone who has been both a decent and crappy significant other in the past, and as someone who strives to be a good one now, I recognized and appreciated much of what Jonze wrote into his film. I enjoyed the honesty, grace and humor that he built into Her. In addition to how well acted the film is (Joaquin Phoenix and Amy Adams are remarkable, as is Johanssons voice performance), it is largely in thanks to these offerings that it takes very little time for the viewer to reconcile the relationship between Theo and an his operating system. There are treats for every audience member who has been in love or in a relationship. There are experiences that warmly resonate, and times where one is inclined to yell at the screen to discourage the characters from going down paths well known to deteriorate into strife. For a film that is in part about our relationship with machines, it is packed with humanity and humor, as it is ultimately about our relationship with ourselves and the people we love.

Not to mention that it is about sexy operating systems that have orgasms, create artificially intelligent manifestations of long dead philosophers, and make hilarious illustrations of armpit sex.

More:
Go see Her, that movie about a guy who falls in love with his operating system